The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
The George Institute for Global Health, University of New South Wales, New Delhi, India.
J Hum Hypertens. 2023 May;37(5):422-424. doi: 10.1038/s41371-023-00816-y. Epub 2023 Apr 11.
In a first of its kind assessment in cardiovascular research, we assessed whether pooled cardiovascular expertise could accurately predict efficacy and tolerability for both a novel and an established treatment option. A survey was administered prior to the publication of the QUARTET (A Quadruple UltrA-low-dose tReatment for hypErTension) trial. QUARTET was a multicentre, double-blind, parallel-group, trial that randomised participants to initial treatment with either monotherapy or an ultra-low dose quadruple single pill combination for 12 weeks. Survey participants were asked to predict blood pressure (BP) at 12 weeks and 52 weeks for both groups.
在心血管研究中首次进行的评估中，我们评估了汇集的心血管专业知识是否可以准确预测新型和已确立的治疗选择的疗效和耐受性。在 QUARTET（四重超低剂量治疗高血压）试验发表之前进行了一项调查。QUARTET 是一项多中心、双盲、平行组试验，将参与者随机分配至初始单药治疗或超低剂量四联单药治疗 12 周。调查参与者被要求预测两组的 12 周和 52 周的血压（BP）。
